Votre navigateur ne supporte pas le javascript Wallonia & Brussels against COVID-19 - Company


Alain Bosseloir, COO

" Development of specific IVD products to detect the patient serology due to the infection with SARS-COV2 Developement based on ISO13485, Directives 98/79/EC standards. Different technologies approched : ELISA, RT-PCR, lateral flow "
Contact: Alain Bosseloir COO ZenTech sa Liege Science Park Avenue du Pré Aily 10 4031 Angleur

Alexandre Di Paolo, Business Development Manager

Xpress Biologics
" Xpress Biologics, a Belgian based CDMO, has several strategies to tackle the COVID-19 pandemic which includes: - The development of a serology assay to detect Covid-19 seroconversion in humans based on the manufacturing of 3 specific COVID-19 antigens ( full-length Spike protein, S1 subunit, RBD domain) using Pichia pastoris as expression system - Plasmid DNA manufacturing expertise for the development of anti-COVID DNA vaccines - Recombinant protein or antibody fragments manufacturing expertise for diagnostic and treatment of COVID-19 Xpress Biologics has adapted technological platforms that are available to meet the COVID-19 pandemic challenge. In particular our Molecular Biology solution can rapidly help us develop microbial strains for robust and efficient expression of several type of biologics such as viral antigens, neutralizing antibody fragments and DNA vaccines while through our Upstream Process platform we can rapidly engineer industrial processes for...

Alexandre Le Vert, Executive Chairman and Cofounder

" OSIVAX is using its proven vaccination approach in Influenza (OVX836 currently in phase 2a clinical trial) to develop a broadly protective coronavirus vaccine triggering CD8 T-cell responses against the Nucleocapsid. This approach is based on evidence that CD8 T-cell responses against Nucleocapsid are protective in animals and humans. OSIVAX is currently down-selecting Nucleocapsid sequences with the aim to produce first lab-scale batches in the coming weeks. "
Funding: OSIVAX is currently seeking funding from European institutions supporting the development of vaccines against COVID-19.
Contact: Alexandre Le VERT This email address is being protected from spambots. You need JavaScript enabled to view it.

Alfred Attipoe, CEO

Comunicare Solutions
" Comunicare Solutions is a health technology startup, specializing in patient empowerment, self-management and digital therapy. In the context of Covid-19 sanitary crisis, we proposed our solution for the remote support to chronic patients, especially the most at risk patients who suffered from chronic systemic diseases of respiratory origin, such as chronic obstructive pulmonary disease (COPD) and heart disease like heart failure or complex hypertension. The application enables caregivers to inform those patients about additional precautions, to screen patients reported outcomes but also to keep in touch with them via video consultation"
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

Cedric Szpirer, Executive & Scientific Director

Delphi Genetics SA
" The aim of the project is to develop an antiviral gene therapy specifically targeting Covid-19. The benefits should be (i) targeting precisely the virus directly in lung cells allowing limitation of virus development from the starting point, (ii) restoring essential functions of the patient's cells and (iii) antibodies production by the patient due to reduction of viral load but not immediate clearance. In addition, the therapy could also be used preventively for people who come into regular contact with affected patients. The therapy is a gene therapy using AAV for patient administration. Delphi Genetics is developing and producing the plasmids required for targeting the virus and production of AAV. "
Contact: Cedric Szpirer Delphi Genetics SA 071 25 10 00

Claude Dedry, CEO

" SalamanderU and Solidfog Technologies are two companies with expertise in innovative customised containment solutions and industrial biotechnology operations, and the second specialises in airborne surface decontamination systems (hydrogen peroxide - H2O2 nebulisation). They have collaborated to provide a simple and robust operational solution for the decontamination of FFP2 masks in large quantities and to be installed directly within the hospital environment. The solution consists of a "CleanBubble®" containment chamber, which can be assembled in less than half an hour, consisting of a flexible envelope attached to an aluminium structure, a vacuum unit equipped with a HEPA filter and a "DosyMist®" decontamination unit that generates an H2O2 mist. This containment chamber is also equipped with the digital "SmartReg®" solution which vocally controls the operators during disinfection and automatically generates a decontamination report. The solution allows to disinfect...

Damien BERTRAND, Business Development Officer

" Research projects : contributions to research projects with academics and hospital representatives (-omics data investigations, biomarkers and multi-marker indicators, stratification of populations, predictive models for diagnosis/prognosis, ... Development / production capabilities: internal processes and quality system compatible with ISO.13485 (medical devices). Skills and expertise: data sciences, machine learning and other technologies from artificial intelligence; statistics, bio-IT; model encapsulation into software, mobile apps or web platforms "
Funding: Prestations sub-contracted by lead researchers, or partnerships through regional/EU projects with public funding.
Publication References: Complete list on www.dnalytics.com/publications/ 
Contact : This email address is being protected from spambots. You need JavaScript enabled to view it.

Denis GOSSEN, CSO, co-founder

" Experts in the early development of drugs and medical devices up to clinical proof-of-concept (from preclinical to Phase 2). Via its network of partners, Aepodia facilitates access to patients and to validated clinical centres throughout Europe. With offices in Belgium and France, Aepodia is a recognized partner for pharmaceutical and biotechnology companies since 2007. "
Contact: www.aepodia.com This email address is being protected from spambots. You need JavaScript enabled to view it.

François Roland- Martin Waroux - Elodie Wannez - Delphine Dauby

UMONS ; FabLab Mons ; Fab-C Charleroi Métropole ; FabLab Wapi
" Visors for face masks produced at FabLab Mons. In collaboration with Fab-C Charleroi Métropole and FabLab Wapi, FabLab Mons is currently producing visors for nursing staff. These visors extend the life of the masks by preventing splash contamination. This has been made possible with the financial support of the FRMH and the donation of transparent sheets from multiple organisations, which has enabled the FabLab to distribute several thousand visors (23,000+ distributed to date) to medical doctors, nurses, pharmacists, physiotherapists, nursing home staff, opticians and audiologists. "
Contact: FabLab Mons https://fablabmons.be This email address is being protected from spambots. You need JavaScript enabled to view it.

Frédéric de Meulemeester, Technical Director

AMB Ecosteryl
" AMB Ecosteryl (Mons), specialized in the treatment and sterilization of medical waste, has adapted its technology to develop a machine that decontaminates these masks (and therefore reuse them afterwards). This machine, named "M-steryl", allows, thanks to dry heat, to decontaminate 1.400 masks per day. This machine can easily be installed in hospitals, allowing staff to decontaminate their equipment individually. It requires only a power outlet and is easy to use. Each mask can be decontaminated three times, allowing for greater autonomy in terms of supply and lower costs. "
Contact: http://ecosteryl.com

Hugues Bultot, CEO

" The current COVID19 pandemic has imposed in a few months a global burden on humanity. A vaccine is urgently needed to protect people, communities, healthcare systems, and economies. In this context, Univercells joined forces with Reithera and Leukocare to develop and manufacture a novel adenovirus-based vaccine against COVID19. This vaccine candidate is expected to enter in clinical trials during summer 2020 and production to start soon after. Capitalizing on the bioproduction technologies of its newly created subsidiary Univercells Technologies, Univercells will produce at large-scale the vaccine candidate in Jumet. This site with 15,000 m² GMP capabilities offers the capacity to be ready for rapid response programs. Approximately 6 million doses are expected to be available in early 2021. The intention with these doses will be to vaccinate the most exposed people such as medical and healthcare professionals and highly vulnerable individuals. "
Publication References...

Jean-Marie Saint-Remy, Professor

Equaly sa
" A novel strategy to prevent virus entry through the ACE2R A novel strategy for preventive vaccination to Covid-19 Monoclonal antibodies targeting the ACE2R are used to block virus entry. Vaccines are prepared eliciting a Th1response together with cytotoxic T cells. "
Funding: private
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

Jean-Paul Deslypere, MD

Aesculape CRO Belgium BV
" Treatment of COVID 19 complications with antibodies "
Funding: partly public partly private
Contact : This email address is being protected from spambots. You need JavaScript enabled to view it. 0492 735931

Jurgen Alexius, CEO

" Deltrian has developed four complete production lines for surgical masks (production and packaging) which will be operational in Fleurus from the end of May 2020. Deltrian will produce 160 surgical masks per minute following a work divided into two breaks. That is a total of 60 million masks per year. A shift to three breaks could even increase production to 90 million masks per year. In response to a request from the federal government and together with the company Sioen (Ardooie, West Flanders), Deltrian will also have the task of producing 20 million filters that will be used to improve the quality of cloth masks that will be compulsory to wear on public transport from 4 May 2020. This is part of a desire to repatriate certain know-how to Wallonia and is an integral part of the Region's reindustrialisation strategy. "
Contact: http://www.deltrian.com/

Contact us

c/o F.R.S. - FNRS

Rue d’Egmont 5

B - 1000 Bruxelles

Tél : +32 2 504 92 11


Brussels & Wallonia against COVID19